Publications by Research Teams who Received Biospecimens from NMVB

To Site NMVB please use the following: This work is funded and supported by the Centers for Disease Control and Prevention (CDC) in association with the National Institute for Occupational Safety and Health (NIOSH) Grant, National Mesothelioma Virtual Bank (5U24OH009077-011).
 

Research Teams who Received Biospecimens from NMVB (chronological order, LOI requestor bolded):

Total Peer Reviewed Publications to Date= 13:

2009:

Crisanti MC, Wallace AF, Kapoor V, Vandermeers F, Dowling ML, Pereira LP, Coleman K, Campling BG, Fridlender ZG, Kao GD, Albelda SM. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther. 2009 Aug;8(8):2221-31. doi: 10.1158/1535-7163.MCT-09-0138. Epub 2009 Aug 11. PMID: 19671764 PMCID: PMC3605895
Citation: 54
Journal Impact Factor: 19.453

Cao X, Littlejohn J, Rodarte C, Zhang L, Martino B, Rascoe P, Hamid K, Jupiter D, Smythe WR. Up-regulation of Bcl-xl by hepatocyte growth factor in human mesothelioma cells involves ETS transcription factors. Am J Pathol. 2009 Nov;175(5):2207-16. doi: 10.2353/ajpath.2009.090070. Epub 2009 Oct 15. PMID: 19834061
Citation: 17
Journal Impact Factor: 2.514

2010:

Vassiliki Saloura, Liang-Chuan S. Wang, Zvi G. Fridlender, Jing Sun, Guanjun Cheng, Veena Kapoor, Daniel H. Sterman, Ronald N. Harty, Atsushi Okumura, Glen N. Barber, Richard G. Vile, Mark J. Federspiel, Stephen J. Russell, Leslie Litzky, and Steven M. Albelda. Evaluation of an Attenuated Vesicular Stomatitis Virus Vector Expressing Interferon-β for Use in Malignant Pleural Mesothelioma: Heterogeneity in Interferon Responsiveness Defines Potential Efficacy. Human Gene Therapy. January 2010, 21(1): 51-64. PMID: 19715403 PMCID: PMC2829454
Citation: 41
Journal Impact Factor: 2.436

Bhatia K, Modali R, Goedert JJ. Merkel cell polyomavirus is not detected in mesotheliomas. J Clin Virol. 2010 Feb;47(2):196-8. Epub 2009 Dec 16. PMID: 20006539 PMC2818524
Citation: 11
Journal Impact Factor: 3.016

Chaturvedi AK, Caporaso NE, Katki HA, Wong HL, Chatterjee N, Pine SR, Chanock SJ, Goedert JJ, Engels EA. C-reactive protein and risk of lung cancer. J Clin Oncol. 2010 Jun 1;28(16):2719-26. doi: 10.1200/JCO.2009.27.0454. Epub 2010 Apr 26. PMID: 20421535 PMCID: PMC2881850.
Citation: 81
Journal Impact Factor: 18.428

Gretchen V. Gee, Devin C. Koestler, Brock C. Christensen, David J. Sugarbaker, Donatella Ugolini, Giovanni P. Ivaldi, Murray B. Resnick, E. Andres Houseman, Karl T. Kelsey, Carmen J. Marsit Downregulated MicroRNAs in the Differential Diagnosis of Malignant Pleural Mesothelioma. Int J Cancer. Author manuscript; Published in final edited form as: Int J Cancer. 2010 December 15; 127(12): 2859–2869. doi: 10.1002/ijc.25285. PMCID: PMC2911512
Citation: 67
Journal Impact Factor: 5.085

2013:

Xu Y, Zheng M, Merritt RE, Shrager JB, Wakelee H, Kratzke RA, Hoang CD. miR-1 induces growth arrest and apoptosis in malignant mesothelioma. Chest. 2013 Nov;144(5):1632-43. doi: 10.1378/chest.12-2770.
Citation: 13
Journal Impact Factor: 7.132

Zhang X, Shen W, Dong X, Fan J, Liu L, Gao X, Kernstine KH, Zhong L. Identification of novel autoantibodies for detection of malignant mesothelioma. PLoS One. 2013 Aug 19;8(8):e72458. doi: 10.1371/journal.pone.0072458. PMID: 23977302 PMCID: PMC3747111
Citation: 2
Journal Impact Factor: 3.234

Song JY, Siegfried JM, Diergaarde B, Land SR, Bowser R, Stabile LP, Dacic S,Dhir R, Nukui T, Romkes M, Weissfeld JL. Genetic variation in ESR2 and estrogen receptor-beta expression in lung tumors. Cancer Epidemiol. 2013 Aug;37(4):518-22. doi: 10.1016/j.canep.2013.03.020. Epub 2013 Apr 23.201
Citation: 3
Journal Impact Factor: 2.711

2014:

Dabir S, Kluge A, Kresak A, Yang M, Fu P, Groner B, Wildey G, Dowlati A. Low PIAS3 expression in malignant mesothelioma is associated with increased STAT3 activation and poor patient survival. Clin Cancer Res. 2014 Oct 1;20(19):5124-32. doi: 10.1158/1078-0432.CCR-14-1233. Epub 2014 Aug 14.PMID: 25124686.
Citation: 8
Journal Impact Factor: 8.72

2015:

Snehal Dabir, Adam Kresak, Michael Yang, Pingfu Fu, Gary Wildey, Afshin Dowlati. CD30 is a potential therapeutic target in malignant mesothelioma. Mol Cancer Ther. Author manuscript; available in PMC 2016 March 1. Published in final edited form as: Mol Cancer Ther. 2015 March; 14(3): 740–746. Published online 2015 January 14. doi: 10.1158/1535-7163.MCT-14-0972.PMID: 25589494 PMCID: PMC4456236.
Citation: 1
Journal Impact Factor: 5.085

Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Baumann F, Zhang YA, Gazdar A, Kanodia S, Tiirikainen M, Flores E, Gaudino G, Becich MJ, Pass HI, Yang H, Carbone M. High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma. J Thorac Oncol. 2015 Jan 30. PMID: 25658628.
Citation: 0
Journal Impact Factor: 5.282

2017:

De Rienzo A, Cook RW, Wilkinson J, Gustafson CE, Richards WG, Amin W, Johnson CE, Oelschlager KM, Maetzold DJ, Stone JF, Feldman FD, Becich MJ, Yeap BY, Bueno R, Gene Expression-Ratio Test Validation in Formalin-Fixed, Paraffin-Embedded Mesothelioma Tissues. Journal of Molecular Diagnostics. 2017 Jan 31;19(1):65-71.